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Abstract
Background—This study examined the predictive value of different classes of markers in the 
progression from Mild Cognitive Impairment (MCI) to Alzheimer’s disease (AD) over an 
extended 4 year follow-up in ADNI.
Methods—MCI patients assessed on clinical, cognitive, MRI, PET-FDG, and CSF markers at 
baseline, and followed on a yearly basis for four years to ascertain progression to AD. Logistic 
regression models were fitted in clusters including demographics, APOE genotype, cognitive 
markers, and biomarkers (morphometric, PET-FDG, CSF Abeta and tau).
Results—The predictive model at four years revealed that two cognitive measures, an episodic 
memory measure and a clock drawing screening test, were the best predictors of conversion 
(AUC= 0.78).
Conclusions—This model of prediction is consistent to the previous model at two years, thus 
highlighting the importance of cognitive measures in progression from MCI to AD. Cognitive 
markers were more robust predictors than biomarkers.
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1. Introduction
The prevalence of dementia is approximately 24.3 million people worldwide, with 
predictions that this amount will be doubled every 20 years [1]. Among the causes of 
dementia, Alzheimer’s disease (AD) is the most common. AD dementia is currently 
considered as an end state after consistent pathologic brain changes have accumulated, 
perhaps years before earliest clinical symptoms manifest.
Relatively few studies have directly compared the differential contribution of different kind 
of markers (biomarkers and cognitive markers) in their predictive utility for the conversion 
from Mild Cognitive Impairment (MCI) to AD. This motivated us to undertake a systematic 
and comprehensive examination of several classes of markers. In a previous study, we found 
that a combination of delayed verbal episodic memory measures and a middle temporal lobe 
cortical thickness measure were the strongest predictive factors of the conversion to AD 
from MCI in a follow-up period of two years, using a sample from the Alzheimer’s disease 
Neuroimaging Initiative (ADNI) [2].
Since our initial report, several studies investigating combination of different markers, have 
obtained similar findings. Ewers et al [3] found that memory measures (free recall) and 
executive function measures had comparable predictive accuracy to that of biomarkers 
within ADNI database, using an approach involving a cross-validation paradigm to 
differentiate AD from elderly control subjects that was later applied to the prediction of MCI 
conversion to AD. Heister et al found that MCI patients with combination of both, learning 
impairment and increased hippocampal atrophy, as having highest risk of conversion to AD 
[4]. Jedynak et al [5], using advanced statistical methods, found that inflection of a delayed 
memory measure preceded that of other biomarkers (CSF levels and hippocampal volumes) 
on the progression from MCI to AD in the ADNI database. This set of findings was recently 
the subject of an editorial that highlighted the otherwise often undervalued importance of 
cognitive measures as early markers of AD progression [6].
In this study, the first aim was to derive a model for prediction and contrast it with our prior 
model findings, but here over a longer follow-up period of four years in the ADNI database. 
Given the often undervalued but widespread phenomenon of failure-to-replicate in published 
biomedical research [7, 8], we believe that confirming the validity of a model of prediction 
for the transition from MCI to AD is of great value, as well as it contributes to clarify the 
processes of this transition.
We appreciate that this is not a replication in a separate and independent sample. 
Nevertheless, as an extension and refinement of our results, we think that this approach will 
be a step toward validation of our overarching findings (that cognitive measures were robust 
predictors of conversion from MCI to AD).
We hypothesized that measures of episodic memory and brain morphometric measures will 
still be predictive of the development of AD in a longer follow-up. To further test this 
hypothesis we also included new biomarkers that we did not evaluate in our previous work: 
1) a recently proposed factor that has been implicated in the risk of AD development, 
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namely CSF linear combination of Aβ1-42 and p-tau181p [9]; 2) fluorodeoxyglucose positron 
emission tomography (FDG-PET) biomarkers, specifically the hypometabolic convergence 
index (HCI), a single measure intended to reflect the extent to which the pattern and 
magnitude of cerebral hypometabolism in an individual correspond to that in probable AD 
patients [10]; this measure has been shown to be predictive of AD progression in MCI alone 
or in combination with hippocampal volume.
2. Methods
2.1. Participants
Data used in the preparation of this article were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (www.loni.ucla.edu\ADNI). Data were 
downloaded on April 18th 2012.
In the present study, we restricted our analyses to the MCI subjects recruited by ADNI-1 
followed for a period of 4 years. Furthermore, we also sought to extend our model, including 
a recently proposed model of the combination of AB and p-tau for the prediction of 
conversion, within the same analytic framework that we utilized in our previous study. 
Inclusion criteria for MCI and healthy subjects are described elsewhere [2] and in the ADNI 
website (http://www.adni-infor.org). Briefly, MCI patients had Mini-Mental State Exam 
(MMSE) [11] scores between 24 and 30 (inclusive), a memory complaint, objective memory 
loss, a Clinical Dementia Rating (CDR) [12] score of 0.5, absence of significant impairment 
in other cognitive domains, and preserved activities of daily living. In an attempt to ascertain 
conversion to AD, we excluded MCI subjects whose conversion to AD was not verified at 
another additional follow-up (i.e. at least two visits being diagnosed as MCI). In addition, if 
MCI patients converted to AD, and AD status did not remain at one further follow-up, 
subjects were also excluded from analysis. All participants signed written informed consent 
for participation in the ADNI, as approved by the institutional board at each participating 
center.
2.2. Procedures
2.2.1. CSF Measures—Details of acquisition are available at ADNI webpage and upon 
request of the authors. Concentrations of Aβ1-42, t-tau and p-tau181p in CSF have been have 
been reported as strongly associated with development of AD [13], and accurate in 
identifying incipient AD [14]. We utilized log transformed values for Aβ1-42, t-tau and p-
tau181p, as well as for t-tau/Aβ1-42, p-tau181p/Aβ1-42, and Aβ1-42/p-tau181p ratios. Since some 
reports have indicated that Aβ1-42 influence on brain volumetric and cognitive decline 
measures only occurs in the presence of elevated p-tau181p [9, 15], we also included a 
measure of the linear combination of Aβ1-42 and p-tau181p that has not been previously 
tested on their predictive utility for conversion to AD. According to published ADNI 
proposed CSF cutoffs values [16], we classified the subjects based on high or positive (>23 
pg/mL) and low or negative (<23 pg/mL) p-tau181p levels, and low or positive (<192 pg/mL) 
and high or negative (>192 pg/mL) Aβ1-42 levels. We calculated a new ordinal variable with 
the combination of these cutoffs levels that yielded 4 levels: high AB and low p-tau codified 
as 1, high AB and high p-tau codified as 2, low AB and low p-tau codified as 3, and finally 
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low AB and high p-tau codified as 4. Subjects classified as having high AB (positive AB) 
and high p-tau (positive p-tau) were greater in the MCI converters group (82.1%) compared 
to non converters (53.1%) [X2= 16.27, p= 0.001].
2.2.2. FDG-PET Acquisition and processing—A fluorodeoxyglucose positron 
emission tomography (FDG-PET) measure involving a voxelwise approach, the HCI, was 
used. This is a single measure intended to reflect the extent to which the pattern and 
magnitude of cerebral hypometabolism in an individual correspond to that in probable AD 
patients [10]. It also has been shown to be predictive of AD progression in MCI alone or in 
combination with hippocampal volume and episodic memory [17].
A specified reconstruction algorithm for each scanner type was implemented according to a 
standardized protocol to acquire FDG-PET data (www.loni.ucla.edu/ADNI/Data/
ADNI_Data.shtml). All images were preprocessed by the ADNI PET coordinating center. 
The processing involved a voxelwise approach to analyze the data using statistical 
parametric mapping (SPM) performed by the Banner Alzheimer’s Institute. Briefly, a 
hypometabolic convergence index (HCI) was calculated for each subject as detailed in Chen 
et al 2011 [10]; this index intended to characterize the extent of cerebral metabolic rate for 
glucose (CMRgl) reductions in each person compared to the reductions people with 
probable AD.
2.2.3. MRI Acquisition and processing—The scans used in this study were obtained 
from 1.5 Tesla scanners at different sites involved in ADNI with minor variations in the 
MRI protocol based on the specific configuration of each scanner. For the purpose of the 
present study, volumetric measures of the whole brain, ventricles, and left and right 
hippocampus, as well as cortical thickness measures of both left and right middle temporal, 
infero-temporal, and entorhinal cortex were investigated as derived by Freesurfer. Detailed 
description of MRI protocol and methods is available at ADNI webpage and upon request of 
the authors.
2.2.4. Cognitive Assessment—ADNI neuropsychological protocol followed guidelines 
to maximize inter-rater reliability and standard administration. The measures included in this 
study were the following: ADAS-Cog word recall, recognition, naming, number 
cancellation, and constructional and ideational praxis tests [18]; the Clock Drawing test [19]; 
Wechsler Memory Scale logical memory, and digit span test [20]; Rey auditory verbal 
learning test [21]; semantic category fluency test [22]; Trail Making test parts A and B [23], 
and Wechsler Adult Intelligence Scale digit symbol substitution test [24].
2.3. Statistical Analyses
Demographic, clinical, biomarkers and cognitive markers were compared between groups 
using t tests. Chi square tests were used to compare dichotomous variables.
To estimate the potential effects to predict conversion from MCI to AD of different sets of 
baseline variables we fitted logistic regression models following a stepwise procedure. The 
primary outcome of interest was change in the diagnostic (from MCI to AD) anytime during 
the 4 years of follow-up. We followed the same approach as on our previous study [2], 
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structured as follows. First, we tested the predictive validity, sensitivity and specificity of 
the best model we obtained in 2 years of follow-up but now applied to the 4 year follow-up 
data. Next, we performed sets of logistic regression analyses grouped in different clusters of 
variables: Demographic variables and genetic risk factor (APOE), CSF biomarkers, MRI 
biomarkers, PET-FDG HCI biomarker, and cognitive markers. This approach was 
undertaken to overcome the difference on sample sizes for each of the markers. From this 
set of clustered regressions models, we then selected only the significant predictors 
(selection of entry was set at p<0.05) and combined them to obtain a final model of 
prediction of conversion to AD. Coefficient of determination in the form of pseudo-R2 was 
used as a measure of the relative predictive power of the models. Predictive accuracy of the 
model was calculated using receiver operating characteristic curve (ROC) analysis. Note 
that age, sex and education were forced in all models.
3. Results
At baseline, 371 patients with MCI were included in the study. 53% were men and the age 
ranged from 55 to 90 years. All the MCI patients had completed cognitive assessment at 
baseline, 330 (88%) of them underwent successful MRI and 163 (44%) successful lumbar 
puncture.
Of the 371 patients diagnosed as MCI at baseline, 150 (40%) developed AD during follow-
up (mean time until conversion 20.44 months; range 5.75–52.63). 168 MCI patients were 
stable at last follow-up (mean follow-up time 33.28 months; range 7.26–61.44).
Demographic, clinical characterization and APOE genotype status of the subjects is 
displayed in Table 1. Cognitive, brain morphometry, and CSF measures are displayed in 
Tables 2–3. The differences between MCI stable and coversion groups were similar to those 
found in our previous report comprising 2 years of follow-up [2]. Differences in almost all 
clinical staging variables, cognitive, brain morphometric variables, FDG-PET and CSF 
measures were found between both groups. Regarding cognitive measures, MCI non-
converters showed similar performance than MCI converters only in digit span (Table 2). 
CSF measures, brain morphometry measure, and FDG-PET hypometabolic convergence 
index (Table 3), measure that was not included in our previous study, also detected 
differences between both MCI groups at baseline (except for ventricular volume that was 
similar between MCI non-converters and MCI converters).
3.1. Application of prior “best model”
By applying the best predictive model of conversion obtained at 2 years of follow-up 
(AVLT delayed, logical memory delayed and left middle temporal lobe thickness) to the 
current 4 years data, we obtained a pseudo-R2 of 0.29 for the model (as compared to 0.34 at 
2 years). The area under the curve was 0.77 (as compared to 0.80 at 2 years), with a 
percentage of cases classified correctly of 68%, a sensitivity of 66%, and a specificity of 
70%, at a probability level of 0.50. The positive predictive value was 0.65 and the negative 
predictive value was 0.70.
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3.2. Use of clustered regression models
In the clustered logistic regression models for the prediction of conversion from MCI to AD 
at 4 years, the findings suggested a very similar pattern to the 2-years follow-up findings 
(Table 4). APOE was a significant predictor of conversion in the demographic and genetic 
risk factor cluster. Among the cognitive markers, AVLT Trial 5 was a significant predictor 
of conversion (instead of AVLT delayed in the 2 year study); ADAS-Cog memory scale 
entered in the model as opposed to the 2 year’s study where it did not predict conversion. 
The same brain cortical thickness measures as those found in the 2 years of follow-up (left 
middle temporal cortex thickness and left hippocampus volume) were still the best 
predictors of conversion at 4 years. Among the CSF biomarkers, T-tau/AB1-42 ratio 
remained predictor of conversion, as it was at 2 years, while the new classification variable 
of the linear combination of AB and p-tau did not reach predictive statistical significance. 
The HCI index of FDG-PET at baseline was also predictive of conversion to MCI in this 
univariate model.
When all the significant predictors of the clustered models (see “winners” model on Table 4) 
were entered in a single predictive logistic regression model, only the cognitive measures, 
AVLT Trial 5 and Clock test score, were found to best predict the development of AD in the 
MCI group of patients (pseudo-R2= 0.32). The receiver operating curve for this model 
showed an area under the curve of 0.78, a percentage of cases classified correctly of 78%, 
sensitivity of 58% and specificity of 74% at a cut-off point of 0.50 (Figure 1). The positive 
predictive value was 0.65 and the negative predictive value 0.67.
3.3. Contrast between old and new model of prediction
Last, we performed a chi-square test to compare the areas under the two different ROC 
curves. This statistical test takes into account both AUCs (prior and current model) and their 
respective standard errors (ChiSq = (AUC1 -AUC2)2/(s12+ s22). The results showed both 
models were not statistically different (X2= 0.35; p= 0.56).
3.4. Patterns of decline in the different classes of markers
Figure 2 shows the difference (in effect size) between baseline and the different follow-ups 
for both groups of MCI (converters and stable). The group of MCI subjects who converted 
to AD showed greater decline in function (ES ranging from medium to large) as measured 
with the Functional Assessment Questionnaire (FAQ) [25], and in cognitive measures such 
as ADAS-Cog, AVLT Trial 5 and semantic fluency (with ES in the small to large range). 
Effect sizes for CSF and brain morphometry measures were small except for medium effect 
of middle temporal thickness, ventricular volume, left entorhinal cortex thickness, and HCI. 
The group of MCI that remained stable at follow-up had all effect sizes in the small range, 
except for FAQ and middle temporal thickness from both hemispheres that were medium 
(0.59 and 0.5 respectively).
4. Discussion
In this prospective study investigating a combination of different classes of biomarkers and 
cognitive markers in predicting development of AD in MCI patients during a follow-up 
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period of four years, two cognitive measures, a verbal episodic memory measure of learning 
(AVLT Trial 5), and a screening measure (Clock drawing test) assessing a combination of 
semantic knowledge, visual motor ability and executive function, were found to be the most 
significant predictors. Furthermore, these findings are strengthened by a complementary 
analysis where patterns of decline on the different markers showed that cognitive measures 
(plus a measure of function) had larger effect sizes in the MCI subgroup that progressed to 
AD.
In our previous study in the same sample, but with a shorter follow-up of 2 years, we found 
that two episodic delayed memory measures (plus left middle temporal thickness) were the 
variables that best predicted conversion to AD [2]. Application of this former predictive 
model to the current 4 year data, yielded an AUC= 0.77 (sensitivity is 66% and specificity is 
70%). In comparison to our initial 2011 model, this reflected a decrease in specificity but an 
increase in sensitivity in the measures’ ability to predict conversion to AD in 4 years of 
follow-up. Nevertheless, and critically, AUC and the pseudo-R2 of our initial model at 2 
years of follow-up were fully comparable to the new “winners” model at 4 years of follow-
up (AUC= 0.78).
Several studies from ADNI, including our original study, have demonstrated that cognitive 
tests are robust predictors of MCI to AD conversion and HC-MCI discrimination [2–5, 17]. 
Studies conducted in other MCI populations (i.e., outside ADNI) have found results similar 
to ours when combining different classes of markers [26, 27]. Furthermore some findings 
place verbal episodic memory impairments (recall and learning) at least 5 years before 
dementia onset [28–30]. An interesting study has indicated that memory decline may be 
indicative of subclinical AD in otherwise healthy individuals as demonstrated by amyloid 
accumulation in PET-amyloid imaging [31]. Individual AUC for neuropsychological 
predictors (AVLT) was in some cases as high as for the combination models [27]. 
Nevertheless, studies outside ADNI have reported higher AUC probabilities as compared to 
our AUCs. Differential characteristics of the MCI samples under examination and different 
sampling procedures may have played role in this discrepancy, as other studies derived from 
ADNI have reported similar AUCs to ours when comparing MCI patients that converted to 
AD to those who remained stable [3].
There are several other issues that deserve comment. First, our new predictive model did not 
include any brain morphometry measure. Although left middle temporal lobe thickness and 
left hippocampus volume were significant predictors in the individual MRI model, they did 
not reach statistical significance when combined with the rest of the markers. One possible 
reason for this might be related to the inclusion of a glucose metabolism measure (FDG-
PET), since when this biomarker was not modeled, both left middle temporal lobe thickness 
and left hippocampus volume (plus episodic memory), were significant predictors of 
conversion in the combined model (data not shown). Furthermore, a complementary analysis 
showed that middle temporal thickness and FDG-PET had greater decline along four years 
than the rest of the brain morphometric measures (See Figure 2). Hence, collinearity and 
sample size issues (subjects with valid measures on all the variables changed as different set 
of variables were fitted together) may have forced the exclusion of MRI measures of the 
final model.
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A second issue relates to our CSF findings. When modeling only CSF measures, P-tau/
AB1-42 ratio was found to be predictive of AD conversion; however this ratio did not 
demonstrate predictive significance when combined with other measures (MRI, FDG-PET 
and cognitive measures) in the final regression model. Therefore, in this MCI sample, CSF 
biomarkers at baseline did not have independent predictive utility when combined with other 
predictors, and additionally did not show significant decline through follow-up. It might be 
possible that this result is related to the stage in the progression of the underlying 
neuropathology in this particular MCI population [32] (i.e. CSF biomarkers have been 
proposed as more informative in very early preclinical states), or increased utility in longer 
follow-ups [33], making these measures perhaps more suitable to identify healthy subjects at 
risk of future AD development.. However, our results suggest that cognitive markers may be 
equally if not more effective as predictors in our study. As opposed to our methods, pre-
clinical CSF studies generally do not directly compare CSF and cognitive markers. 
Additionally, it has also been claimed that Ab associated brain volume loss [15] and clinical 
decline [9] occurs only in the presence of elevated p-tau. However, our findings do not point 
toward strong predictive ability of ptau/AB linear combination on AD progression in MCI.
Third, it is important to note that the number of subjects included in our regression models 
decreased when predictive variables were progressively estimated together, given that fewer 
subjects underwent lumbar punctures, compared to MRI or cognitive assessment; this fact 
may have restricted our ability to adequately compare different clusters of markers in 
simultaneous combination. Our approach to overcome this issue was clustering set of similar 
markers into separate regression analyses, hence maximizing sample size on each model, 
and finally aggregate the resulting significant measures (“winners”) into a final predictive 
model,. Also, we acknowledge that our findings may not be fully generalizable to other 
studies outside ADNI.
Fourth, another factor that could have influenced our findings is related to age of the 
subjects studied. MRI and cognition have been found to remain informative in both older 
and younger patients (as subjects included in our study), unlike CSF biomarkers that only 
are predictive of subsequent AD development in younger individuals [34]. As such 
biological and cognitive markers may have different roles at various points in the 
development of AD, i.e. can be differentially sensitive to changes at different stages of the 
disease [35].
Finally, as our complementary effect size analysis indicated, function as measured by the 
FAQ, showed the highest decline through four years in the MCI converters subgroup. 
However, we did not include it in the predictive models because doing so would create a 
tautology (i.e., function is used to distinguish the MCI and AD diagnoses). Nevertheless, 
empirically, it is a strong predictor of conversion.
In summary, cognitive markers were still predictive of conversion to AD in a MCI 
population at four years of follow-up, as they were found to be at two years of follow-up. 
This set of findings highlights the importance of cognitive measures, even those derived 
from basic clinical neuropsychological tests, in their predictive utility for MCI to AD 
progression.
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RESEARCH IN CONTEXT
Systematic Review
Few studies combining several clinical, cognitive, and biological markers in the 
progression of Mild Cognitive Impairment (MCI) to Alzheimer’s disease (AD) have been 
carried out. We searched PubMed for published studies of combined predictive utility of 
different markers on the progression from MCI to AD, and conducted our analyses in 
ADNI.
Interpretation
Our findings highlight the importance of cognitive measures on the detection of pre-
clinical AD and prediction of progression from MCI to AD both over shorter and longer 
time periods. Cognitive markers perform as robustly, if not more so, than biomarkers in 
unbiased predictive models of the development of AD.
Future Directions
Future studies should compare all classes of markers on integrative models of prediction 
comprising longer follow-ups in at risk groups. Development of novel and sensitive 
measures of episodic memory may be an economical, safe, and empirically promising 
approach to capture changes in prodromal AD and perhaps preclinical AD.
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Figure 1. Receiver Operating Curve (ROC) of the “winners” logistic regression model
Receiver Operating Curve of significant predictors in the “winners” logistic regression 
model. The red line indicates the three demographic variables (age, gender and education) 
forced into the model; the green line indicates the first variable to enter in the model, 
Auditory Verbal Learning Test Trial 5 with an Area Under the Curve (AUC) of 0.72; the 
blue line indicates the last variable to enter the model, Clock test score with an AUC of 0.78.
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Figure 2. Patterns of decline of the different classes of markers
Panel 1 shows the effect sizes for the difference in cognitive and functioning scores between 
baseline and each one of the follow-ups from months 12 to 48 (except for ADAS-Cog test 
from month 12 to 36): 1A for the MCI group that converted to AD, and 1B for the MCI 
group that remained stable. Panel 2 shows effect sizes in MRI morphometry, FDG-PET 
HCI, and CSF biomarkers between baseline and each one of the follow-ups from months 12 
to 36 (measures at month 48 were not available): 2A for the MCI group that converted to 
AD, and 2B for the MCI group that remained stable
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Table 1
Baseline Demographic, Clinical, Functional and APOE Genotype Data
MCI Non-converters (n= 168) MCI Converters (n= 150) Statistical Test P Value
Sex (M/F) 109/59 90/60 X2 = 0.81 0.37
Age, Mean (SD) 75.02 (7.51) 74.92 (7.03) t316 = 0.12 0.90
Years of Education, Mean (SD) 15.77 (3.11) 15.63 (2.91) t316 = 0.41 0.68
CDR sum of boxes, Mean (SD) 1.44 (0.78) 1.82 (0.93) t316 = −3.95 <0.0001
MMSE, Mean (SD) 27.42 (1.72) 26.67 (1.71) t316 = 3.86 <0.0001
APOE Status E2E2= 0
E2E3= 12
E2E4= 3
E3E3= 82
E3E4= 56
E4E4= 15
E4 Carrier (42 %)
E2E2= 0
E2E3= 3
E2E4= 5
E3E3= 46
E3E4= 70
E4E4= 26
E4 Carrier (64 %)
X2 = 19.58 <0.0001
FAQ Score, Mean (SD) * 2.54 (3.43) 5.36 (4.77) t316 = −6.08 <0.0001
*
Missing data for 2 MCI non converters;
MCI: Mild Cognitive Impairment; M: Male; F: Female; SD: Standard Deviation; CDR: Clinical Dementia Rating; MMSE: Mini-Mental State 
Examination; FAQ: Functional Assessment Questionnaire.
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Table 2
Baseline Cognitive Status
MCI Non- converters (n= 168) MCI Converters (n= 150) Statistical Test P Value
ADAS Memory, Mean (SD) 14.00 (5.19) 17.69 (4.43) t316 = −6.78 <0.0001
ADAS NonMemory 1, Mean (SD) 2.71 (2.10) 3.72 (2.54) t313 = −3.88 <0.0001
Logical Memory Immediate, Mean (SD) 7.73 (3.02) 6.42 (3.09) t316 = 3.81 <0.0001
Logical Memory Delayed, Mean (SD) 4.47 (2.65) 2.84 (2.44) t316 = 5.68 <0.0001
Clock Drawing Test, Mean (SD) 4.41 (0.81) 3.95 (1.08) t316 = 4.31 <0.0001
AVLT Trial 5 2, Mean (SD) 8.24 (2.78) 6.43 (1.97) t316 = 6.66 <0.0001
AVLT Delayed 3, Mean (SD) 3.72 (3.69) 1.57 (2.11) t316 = 6.27 <0.0001
AVLT Recognition 4, Mean (SD) 10.41 (3.49) 8.69 (3.73) t316 = 4.26 <0.0001
Category Fluency, Mean (SD) 13.91 (3.71) 12.74 (3.37) t316 = 2.92 0.004
Trails A, Mean (SD) 40.39 (16.00) 48.68 (25.58) t316 = −3.50 0.001
Trails B 5, Mean (SD) 115.04 (61.74) 151.30 (80.79) t313 = −4.50 <0.0001
Digit Span, Mean (SD) 7.17 (1.80) 7.19 (1.67) t316 = −0.09 0.93
Digit Symbol, Mean (SD) 39.52 (10.61) 34.41 (10.58) t316 = 4.30 <0.0001
1
Missing data for 1 MCI non converter and 2 MCI converters;
2
Missing data for 2 healthy subjects;
3
Missing data for 1 healthy subject;
4
Missing data for 1 healthy subject;
5
Missing data for 3 MCI non converters;
FDG-PET: Fluorodeoxyglucose-positron emission tomography; HCI: Hypometabolic convergence index.
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Table 3
Baseline Brain Morphometry and CSF Biomarkers
Brain Morphometry
MCI Non- converters (n= 
152)
MCI Converters (n= 
132)
Statistical Test P value
Whole-brain, Mean (SD)1 1004472 (103950) 979445 (115133) t282 = 1.92 0.06
Ventricles, Mean (SD)1 43850 (22151) 46619 (18878) t282 = −1.12 0.26
Left Hippocampus, Mean (SD)1 3236 (503) 2987 (493) t282 = 4.21 <0.0001
Right Hippocampus, Mean (SD)1 3424 (542) 3152 (568) t282 = 4.13 <0.0001
Left Middle Temporal cortical thickness, Mean 
(SD)2 2.49 (0.19) 2.35 (0.21) t282 = 5.79 <0.0001
Right Middle Temporal cortical thickness, Mean 
(SD)2 2.54 (0.18) 2.41 (0.23) t282 = 5.20 <0.0001
Left entorhinal cortical thickness, Mean (SD)2 2.96 (0.51) 2.76 (0.45) t282 = 3.54 <0.0001
Right entorhinal cortical thickness, Mean (SD)2 3.09 (0.53) 2.86 (0.51) t282 = 3.72 <0.0001
FDG-PET
MCI Non- converters (n= 88) MCI Converters (n= 74) Statistical Test P value
HCI, Mean (SD) 7.14 (3.47) 9.75 (3.88) t160= −4.52 <0.0001
CSF Biomarkers
MCI Non- converters (n= 82) MCI Converters (n= 84) Statistical Test P value
AB, Mean (SD) 5.09 (0.35) 4.94 (0.26) t164 = 3.13 0.002
Total Tau, Mean (SD) 4.38 (0.52)3 4.61 (0.40) t164 = −3.06 0.003
P Tau, Mean (SD) 3.33 (0.52) 3.58 (0.42)4 t164 = −3.46 0.001
Total Tau/AB, Mean (SD)
−0.71 (0.74)3 −0.34 (0.54) t164 = −3.64 <0.0001
P Tau/AB, Mean (SD) −1.76 (0.77) −1.36 (0.57) t164 = −3.81 <0.0001
1
Measured in mm3;
2
Measured in mm;
3N=79, 3 subjects had AB and had not t-tau;
4N=85, 1 subject had p-tau and had not t-tau and AB.
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Table 4
Clustered logistic regression models of conversion over 4 years
OR (95% CI) ΔR2/p
Demographics & APOE (X2= 15.07/p=0.005; AUC=0.62)
APOE 2.41 (1.50–3.91) ΔR2=0.07/p=0.0003
Cognitive Markers (X2= 84.23/p<0.0001; AUC=0.78)
AVLT Trial 5 0.83 (0.73–0.95) ΔR2=0.19/p<0.0001
Logical Memory delayed 0.83 (0.74–0.93) ΔR2=0.05/p=0.0003
Clock Drawing Test 0.65 (0.48–0.86) ΔR2=0.03/p=0.001
Trail Making Test, Part A 1.02 (1.00–1.03) ΔR2=0.03/p=0.01
ADAS-Cog Memory 1.08 (1.01–1.15) ΔR2=0.02/p=0.02
Brain Morphometric Measures (X2= 50.45/p<0.0001; AUC=0.74)
Left Middle Temporal Lobe Thickness 0.03 (0.007–0.12) ΔR2=0.16/p<0.0001
Left Hippocampus Volume 0.999 (0.998– 0.999) ΔR2=0.06/p=0.0002
FDG-PET Measure (X2= 17.96/p<0.0001; AUC=0.70)
HCI 1.21 (1.10–1.34) ΔR2=0.15/p=0.0007
CSF Biomarkers (X2 = 14.66/p=0.005; AUC=0.66)
P-tau/Aβ Ratio 2.34 (1.45–3.91) ΔR2=0.12/p=0.0005
“Winners” Model, i.e., including only previous significant measures (X2= 19.64/p=0.001; AUC=0.78)
AVLT Trial 5 0.65 (0.47–0.85) ΔR2=0.20/p=0.001
Clock Drawing Test 0.43 (0.21–0.85) ΔR2=0.12/p=0.006
OR: Odds Ratio; CI: Confidence Interval; ΔR2: Pseudo-R/square; p: Significance Level; AUC: Area Under the Curve; AVLT: Auditory Verbal 
Learning Test; ADAS-Cog: Alzheimer’s Disease Assessment Scale-Cognitive; CSF: Cerebrospinal Fluid.
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